tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Pseudomonas Infections D011552 25 associated lipids
Psoriasis D011565 47 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Pterygium D011625 3 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Rectal Diseases D012002 1 associated lipids
Rectal Fistula D012003 2 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Respiration Disorders D012120 5 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Retinoblastoma D012175 12 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Rosacea D012393 13 associated lipids
Rotavirus Infections D012400 1 associated lipids
Rupture D012421 2 associated lipids
Sarcoidosis D012507 13 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Osteosarcoma D012516 50 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Sclerosis D012598 5 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Seizures D012640 87 associated lipids
Shock D012769 11 associated lipids
Shock, Septic D012772 11 associated lipids
Sinusitis D012852 9 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Skin Neoplasms D012878 12 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomatitis D013280 14 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Tachycardia D013610 7 associated lipids
Telangiectasis D013684 2 associated lipids
Testicular Diseases D013733 15 associated lipids
Thinness D013851 11 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thrombophlebitis D013924 6 associated lipids
Thrombosis D013927 49 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Tinea D014005 5 associated lipids
Tinea Capitis D014006 1 associated lipids
Tongue Diseases D014060 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Dumont FJ et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. 1990 J. Immunol. pmid:1688572
Woo J et al. Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. 1990 Clin. Exp. Immunol. pmid:1689226
Dumont FJ et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. 1990 J. Immunol. pmid:1689353
Brown Z and Neild GH FK-506 and haemolytic uraemic syndrome. 1990 Lancet pmid:1689442
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Vathsala A et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. 1990 Transplantation pmid:1689520
Yamamoto K et al. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. 1990 Immunology pmid:1689694
Hoffman AL et al. The effect of FK 506 on small intestine allotransplantation in the rat. 1990 Transplant. Proc. pmid:1689907
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Nalesnik MA et al. The effect of FK 506 and CyA on the Lewis rat renal ischemia model. 1990 Transplant. Proc. pmid:1689911
Francavilla A et al. FK 506 as a growth control factor. 1990 Transplant. Proc. pmid:1689912
Mazzaferro V et al. Studies of the hepatotrophic qualities of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689913
Kay JE et al. The mechanism of action of FK 506. 1990 Transplant. Proc. pmid:1689914
Suzuki N et al. Effects of a novel immunosuppressive agent, FK506, on human B cell activation. 1990 Clin. Exp. Immunol. pmid:1690097
Randall T New antirejection drugs anticipated. 1990 JAMA pmid:1696999
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Morris RE et al. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. 1990 Transplant. Proc. pmid:1697111
Woo J et al. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. 1990 Transplant. Proc. pmid:1697112
Woo J et al. Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. 1990 Transplant. Proc. pmid:1697113
Propper DJ et al. Low-dose FK 506 inhibits sensitisation after blood transfusions. 1990 Transplant. Proc. pmid:1697114
Tiebosch A et al. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. 1990 Transplant. Proc. pmid:1697115
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Imai K et al. Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. 1990 Transplant. Proc. pmid:1697117
Siekierka JJ et al. The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. 1990 J. Biol. Chem. pmid:1701173
Johansson A and Möller E Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. 1990 Transplantation pmid:1701570
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Tsuji RF et al. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. 1990 J. Antibiot. pmid:1701765
Granelli-Piperno A et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter. 1990 J. Exp. Med. pmid:1701825
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Takai K et al. Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry. 1990 Clin. Exp. Immunol. pmid:1702372
Okubo Y et al. FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis. 1990 Clin. Exp. Immunol. pmid:1702373
Collier SJ Immunosuppressive drugs. 1989-1990 Curr. Opin. Immunol. pmid:2484794
McCauley J et al. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. 1989 Dec 23-30 Lancet pmid:2481200
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. 1989 Transplantation pmid:2465592
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. 1989 Transplantation pmid:2465593
Takabayashi K et al. Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. 1989 Clin. Immunol. Immunopathol. pmid:2466594
Gschwendt M et al. The immunosuppressant FK-506, like cyclosporins and didemnin B, inhibits calmodulin-dependent phosphorylation of the elongation factor 2 in vitro and biological effects of the phorbol ester TPA on mouse skin in vivo. 1989 Immunobiology pmid:2471685
Fujii Y et al. Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. 1989 Transplantation pmid:2472025
Tocci MJ et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. 1989 J. Immunol. pmid:2472451
Beck Y and Akiyama N Effect of FK-506 and cyclosporine on human lymphocyte responses in vitro. 1989 Transplant. Proc. pmid:2472695
Thomson AW FK-506--how much potential? 1989 Immunol. Today pmid:2473767
Ochiai T et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. 1989 Transplantation pmid:2474208
Ochiai T et al. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. 1989 Transplantation pmid:2474209
Siekierka JJ et al. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. 1989 J. Immunol. pmid:2474605
Thomson AW and Woo J Immunosuppressive properties of FK-506 and rapamycin. 1989 Lancet pmid:2474733
Todo S et al. Renal transplantation in baboons under FK 506. 1989 Surgery pmid:2474865
Leonard DK et al. Toxicity of FK-506 in human fetal pancreas. 1989 Diabetes pmid:2463195
Stephen M et al. Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. 1989 Transplantation pmid:2463701